This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Zidovudine Plus Lamivudine in HTLV-I-associated Myelopathy: a Randomised Trial

This study has been completed.
Information provided by:
Imperial College London Identifier:
First received: January 4, 2006
Last updated: May 27, 2015
Last verified: January 2006
To determine whether the use of two antiviral agents in combination will be better than placebo in the treatment of an inflammatory sidease of the spinal cord caused by HTLV-I

Condition Intervention Phase
HTLV-I-associated Myelopathy Drug: Zidovudine/lamivudine Phase 2 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Zidovudine Plus Lamivudine in HTLV-I-associated Myelopathy: a Randomised Trial

Resource links provided by NLM:

Further study details as provided by Imperial College London:

Primary Outcome Measures:
  • Clinical:
  • Timed walk
  • Pain score
  • Urinary frequency
  • Bowel function
  • Disability scale

Secondary Outcome Measures:
  • Viral load
  • Markers of inflammation
  • Markers of proliferation

Estimated Enrollment: 24
Study Start Date: November 1999
Estimated Study Completion Date: November 2001
Detailed Description:
Randomised, double-blind, placebo-controlled two centre study of zidvoudine plus lamivudine in HAM/TSP 24 patients randomised 1:1 2-4 week lead-in 6 months randomised phase followed by 6 months open-label therapy with active drug Primary endpoint: clinical Secondary endpoints: virological and immunological

Ages Eligible for Study:   16 Years to 75 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

HTLV-I-associated myelopathy -

Exclusion Criteria:

prior exposure to zidovudine or lamvudine on disease modifying therapy under age 16

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00272480

United Kingdom
Imperial College
London, United Kingdom, W2 1PG
Sponsors and Collaborators
Imperial College London
Principal Investigator: Graham P Taylor, FRCP Imperial College London
  More Information

Taylor GP et al The Bridge Study - A double-blind, placebo controlled trial of zidovudine plus lamivudine for the treatment of patients with HTLV-I-associated myelopathy AIDS Research and Human Retroviruses 2003;19 (suppl 1) #O23 Identifier: NCT00272480     History of Changes
Other Study ID Numbers: BRIDGE1.0
Study First Received: January 4, 2006
Last Updated: May 27, 2015

Keywords provided by Imperial College London:
HTLV-I-associated myelopathy
antiretroviral therapy

Additional relevant MeSH terms:
Paraparesis, Tropical Spastic
Spinal Cord Diseases
Bone Marrow Diseases
Central Nervous System Diseases
Nervous System Diseases
Hematologic Diseases
HTLV-I Infections
Deltaretrovirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Central Nervous System Infections
Reverse Transcriptase Inhibitors
Nucleic Acid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents
Anti-HIV Agents
Antimetabolites processed this record on September 21, 2017